20/20 Biolabs Seeks Shareholder Approval for Reverse Stock Split
20/20 Biolabs, Inc. (AIDX) has filed a Definitive Proxy Statement (DEF 14A) announcing a Special Meeting of Stockholders on December 9, 2026. The primary purpose of the meeting is to vote on a proposal to authorize the board of directors to implement one or more reverse stock splits of the Company's outstanding common stock, with ratios ranging from 1-for-2 to 1-for-250, at any time prior to December 31, 2028. This action is primarily intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, with a compliance deadline of January 13, 2027. A second proposal seeks authorization to adjourn the meeting if necessary to solicit additional proxies. The filing also details current share ownership among management and major shareholders.
Key Highlights
- 20/20 Biolabs, Inc. to hold Special Meeting on December 9, 2026, to vote on a reverse stock split.
- Proposal 1: Authorize board to implement reverse stock splits at ratios between 1-for-2 and 1-for-250, effective until December 31, 2028.
- Reason for reverse split: To regain compliance with Nasdaq's $1.00 bid price rule, with a compliance deadline of January 13, 2027.
- The reverse stock split aims to enhance marketability and acceptability of the common stock to investors and financial community.
- If approved, the number of outstanding shares could be reduced from 13,367,204 to as low as 53,468, depending on the ratio chosen.
- Proposal 2: Approve adjournment of the meeting if necessary to solicit additional proxies for Proposal 1.
- Jonathan Cohen, CEO, holds 13.64% of common stock; Streeterville Capital, LLC holds 9.99%.
Price Impact
More from AIDX